{"id":995078,"date":"2026-08-13T16:05:09","date_gmt":"2026-08-13T20:05:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alumis-reports-second-quarter-2026-financial-results-and-highlights-recent-achievements\/"},"modified":"2026-08-13T16:05:09","modified_gmt":"2026-08-13T20:05:09","slug":"alumis-reports-second-quarter-2026-financial-results-and-highlights-recent-achievements","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alumis-reports-second-quarter-2026-financial-results-and-highlights-recent-achievements\/","title":{"rendered":"Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements"},"content":{"rendered":"
\n

\n \u2013 ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO \u2013<\/em>\n <\/p>\n

\n \u2013 Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 \u2013<\/em>\n <\/p>\n

\n
\n \u2013 Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE anticipated in Q3 2026 \u2013<\/em>
\n <\/em>\n <\/p>\n

\n
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended June 30, 2026, and highlighted recent achievements and upcoming milestones.<\/p>\n

\u201cEnvudeucitinib’s Phase 3 clinical validation in PsO, reinforced by our ONWARD3 long-term data, demonstrates the power of maximal TYK2 inhibition in IL-23\/IL-17-driven diseases, and our anticipated Phase 2b LUMUS readout in SLE may substantiate its role in IFN-driven diseases — potentially unlocking broader potential of our TYK2 franchise,\u201d said Martin Babler, President and Chief Executive Officer of Alumis. \u201cThe ONWARD3 long-term data delivered the highest reported PASI 100 response rate among oral therapies, positioning envudeucitinib to set a new standard in PsO. We remain on track to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 with the goal, if approved, of bringing this new oral treatment option to patients.\u201d<\/p>\n

\u201cLooking ahead, our main focus is on realizing our two TYK2 pipeline-in-a-pill franchise opportunities.\u201d Babler added, \u201cBased on the strength of clinical data to date, we are prioritizing Sj\u00f6gren\u2019s disease and cutaneous lupus erythematosus (CLE) as the next indications for envudeucitinib, subject to our LUMUS results and disciplined capital allocation. We are also advancing A-005, our CNS-penetrant TYK2 inhibitor, into a Phase 2 biomarker trial in Parkinson\u2019s disease patients, planned to be initiated in the first half of 2027. Collectively, these programs underscore our goal to leverage the breadth of the TYK2 mechanism to pursue a broad range of immune-mediated diseases.\u201d<\/p>\n

\n Second Quarter 2026 and Recent Highlights<\/strong>\n <\/p>\n

\n Envudeucitinib: a next<\/strong>
\n –<\/strong>
\n generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate<\/strong>
\n –<\/strong>
\n to<\/strong>
\n –<\/strong>
\n severe plaque psoriasis<\/strong>\n <\/p>\n